Document is current
Any future updates will be listed below
-
Authors
Papagiannis, Andreas
Majjaj, Samira
Duhoux, Francois P. https://orcid.org/0000-0002-5429-7888
Agostinetto, Elisa https://orcid.org/0000-0003-0295-7511
Stanciu, Alexandra M.
Vanhulst, Thila https://orcid.org/0009-0006-4806-0370
Buisseret, Laurence https://orcid.org/0000-0002-3751-0819
Larsimont, Denis
Veys, Isabelle
Paesmans, Marianne
Hammer, Tatiana Besse
Awada, Ahmad https://orcid.org/0000-0001-7412-9163
Ameye, Lieveke
Rothe, Francoise
Madriles, Francesc https://orcid.org/0000-0002-5044-0747
Cash, Timothy P.
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Willard-Gallo, Karen https://orcid.org/0000-0002-1150-1295
Sotiriou, Christos https://orcid.org/0000-0002-5745-9977
Vuylsteke, Peter
Neven, Patrick https://orcid.org/0000-0002-1434-9460
Ignatiadis, Michail https://orcid.org/0000-0002-4493-3748
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 7 November 2025
First Online: 26 November 2025
Competing interests
: MI reports consultancy roles for Seattle Genetics, Daichi, AstraZeneca, Menarini/Stemline, Gilead Sciences, and Novartis (all unrelated to the present work), Rejuveron Senescence Therapeutics, grant/research support (to institution) from Roche, Inivata Inc, and Natera Inc (all unrelated to the present work), Pfizer, and uncompensated roles for EORTC (EORTC Board of Directors 2018–2021, Chair EORTC Breast Cancer Group 2021–2025). FPD reports grants from Fondation Belge Contre le Cancer, institutional payments from Roche, Pfizer, AstraZeneca, Eli Lilly, Novartis, Amgen, Daiichi Sankyo, Pierre-Fabre, Gilead, Seagen, and MSD, and support for attending meetings from Amgen, Roche, Teva, Pfizer, Daiichi Sankyo, AstraZeneca, Gilead, and MSD (all unrelated to the present work). ORCID ID: 0000-0002-5429-7888.L.B. reports Research funding to my Institution from Astra Zeneca/MedImmune Advisory role for Domain Therapeutics, iTeos Therapeutics, AstraZeneca Salary partly covered by the Fondation contre le Cancer (Belgium) Member of the IMMUcan Consortium (EORTC) Travel grants from GILEAD, AstraZeneca, Roche (all unrelated to the present work).E.A. reports Research grant to my institution: Gilead Advisory Board for AstraZeneca Receipt of honoraria or consultation fees: Eli Lilly, AstraZeneca, Abscint, Bayer Travel/meeting grants: Eli Lilly, AstraZeneca, Daiichi Sankyo, Abscint, Menarini, Gilead (all unrelated to the present work).ORCID ID: 0000-0003-0295-7511. A.A. reports Advisory role: Amgen, AstraZeneca, Bayer, Daiichi, EISAI, Genomic Health, Hengrui, Innate, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Menarini Speaker fees: Amgen, AstraZeneca, Bayer, Daiichi, EISAI, Genomic Health, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Hikma, Sothema. Research grants to the Institute: BMS, Roche (all unrelated to the present work). R.S. reports Advisory Board role for BMS, Roche, Exact Sciences, Daicchii Sankyo, Astra Zeneca, Case45. Research funding by Roche, Puma, Merck, BMS and Travel and congress-registration support by Roche, Merck, Astra Zeneca (all unrelated to the present work).F.M. and T.P.C. are employes of Rejuversen. The remaining authors declare no other competing interests.
